Surgical resection of resectable thoracic metastatic hepatocellular carcinoma after liver transplantation  by Zhang, Chong et al.
Surgical resection of resectable thoracic metastatic hepatocellular
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BRIEF TECHNIQUE REPORTSAlthough the role of orthotopic liver transplantation (OLT)
in the treatment of hepatocellular carcinoma (HCC) has
improved over the years, tumor recurrence is still a major im-
itation of long-term survival even after radical transplanta-
tion treatment.1 Thoracic metastasis is the most common
site of extrahepatic spreads. The role of surgery for thoracic
metastasis is not known, and until now there have been few
reports about surgical resection for thoracic HCC metastasis
after liver transplantation. We evaluate the surgical efficacy
in the treatment of thoracic HCC recurrence after OLT.
CLINICAL SUMMARY
Between October of 2003 and September of 2007, 5 pa-
tients who had undergone OLT for HCC demonstrated
resectable thoracic HCC recurrence and were admitted to
the Department of Thoracic and Cardiovascular Surgery
without other identifiable recurrence foci. Thoracic recur-
rence was located in the right lower lobe and the upper
lobe in 1 patient, the right lower lobe in 1 patient, the
fourth to sixth right costal cartilage and the right lower
lobe in 1 patient, the middle lobe in 1 patient, and the right
upper lobe in 1 patient. They underwent standard lobec-
tomy or wedge resection for thoracic recurrence. The spec-
imen pathology showed all low differentiated metastatic
HCC, except a benign nodule of the right lower lobe in
the patient with recurrence in the costal cartilage. After sur-
gical resection, no patient received chemotherapy or other
adjuvant treatments. Patients were followed up at interval
with laboratory analysis and whole body scan for physical
conditions and a second recurrence. HCC recurrence devel-
oped in the left adrenal gland in 1 patient 6 months after
right lower lobectomy. Left adrenal gland resection was
performed under laparoscopic surgery, and the pathology
revealed low differentiated metastatic HCC. The other 4
patients have no recurrence, and all 5 patients are currently
alive. The time from transplant to diagnosis of thoracic
recurrence ranged from 8 to 33 months, with an average
period of 18.6 months. The survival time from transplant
ranged from 16 to 85 months, with a mean time of 37.4
months. The survival time from thoracic resection ranged
from 3 to 53 months, with an average time of 17.8 months.
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All thoracic surgical management, survival time, and other
clinical parameters are reviewed in Table 1.
DISCUSSION
Liver transplantation was considered as radical surgery
macroscopically (the tumor is resected completely and there
is no residual tumor tissue from surgeon’s eye and radiogra-
phy) for patients with HCC. However, tumor recurrence was
the major limitation of long-term survival after liver trans-
plantation. Although intrahepatic recurrence predominated,
the most common location of extrahepatic metastasis was
the thorax.2 Survival for patients with recurrence was signif-
icantly shorter than for patients undergoing transplantation
for HCC without recurrence. Thoracic recurrence was
mainly detected by biochemical and radiographic evidence.
Increased alpha-fetoprotein level was generally an early key
indicator for any advanced radiographic evidence of HCC
recurrence. Enhanced computed tomography, ultrasonogra-
phy, positron emission tomography, and radionuclide bone
imaging were also important as routine initial or advanced
screening for recurrence evidence.
Although some studies have shown that only adjuvant
treatments for posttransplant HCC recurrence without surgi-
cal resection may be good to increase survival, a better ben-
efit may be obtained from metastasectomy.3 The type of
surgical resection was based on the patients’ anatomic and
physiologic considerations. Radical lobectomy was pre-
ferred, and wedge resection was considered according to
the recurrence anatomic site, numbers, pulmonary function,
and even the request of the patients. All 5 patients are cur-
rently alive, and the average survival time from thoracic re-
section is 17.8 months, which is similar to the results of
previous reports.3 Although the size of our study population
was small, the survival time in these patients is encouraging.
A larger study may be necessary to assess the possible bene-
fits of surgical resection and surgical types for resectable tho-
racic metastasis after liver transplantation for HCC. These
aims should be accomplished with advanced investigation
in a larger population and a longer follow-up for similar
patients.
CONCLUSIONS
There have been few reports about surgical resection for
thoracic metastasis after liver transplantation for HCC. In
our series, metastasectomy for resectable thoracic HCC re-
currence after liver transplantation was encouraging and is
suggested as a reasonable treatment.rgery c July 2009
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TABLE 1. Characteristics of patients and data of recurrence, metastasectomy, survival time
Patient 1 2 3 4 5
Gender Male Male Male Male Male
Age, y 49 66 47 63 37
Thoracic recurrence
Location RUL, RLL RLL RCC, RLL RML RUL
Size (cm) 1, 2 3.5 5, 0.5 3 1
Resection Wedge Lobectomy Rib resection, Lobectomy Wedge Wedge
Tumor differentiation grade Low, low Low Low, benign Low Low
Postresection treatment No No No No No
Secondary recurrence No Yes No No No
Location — Left adrenal gland — — —
Size (cm) — 3 — — —
Resection — Laparoscope — — —
Tumor differentiation grade — Low — — —
Postresection treatment — No — — —
Alive Yes Yes Yes Yes Yes
Time from transplant (mo)
to thoracic recurrence 32 33 12 8 11
to secondary recurrence — 39 — — —
Survival time from TRR (mo) 53 16 8 9 3
RUL, Right upper lobe; RLL, right lower lobe; RCC, right costal cartilage; RML, right middle lobe; TRR, thoracic recurrence resection.
Brief Technique ReportsRadio-guided surgery for ventricular remodeling in patients with
ischemic dilated cardiomyopathy: A new tool to discriminate in vivo
viable myocardium and scar
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Acombined surgical procedure, left ventricular restoration
(LVR), which consists of coronary artery bypass grafting
and endoventricular patch plasty (EPP), is under investiga-
tion in the on-going Surgical Treatment for Ischemic Heart
Failure trial.1 EPP can provide restoration of left ventricular
(LV) size and geometry by excluding nonviable areas. At
present, the differentiation of viable tissue and scar tissue
is based on using subjective methods to assess morphologic
features, such as consistency, thickness, and color of the
wall, and it might be inadequate on the surgical table. We as-
sessed the feasibility of in vivo radio-guided surgery (RGS)
with a gamma probe as an objective tool to differentiate
viable tissue and scar tissue in patients undergoing EPP.
CLINICAL SUMMARY
Two patients with previous anterior myocardial infarc-
tions were selected for LVR (Table 1). Informed consent
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